Published in Biochem Pharmacol on November 15, 1987
Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc Natl Acad Sci U S A (1994) 2.56
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest (1993) 2.27
Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother (1992) 2.15
Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci U S A (1991) 1.67
Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother (1997) 1.66
Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother (1989) 1.40
Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J Virol (2002) 1.36
Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob Agents Chemother (1994) 1.33
Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc Natl Acad Sci U S A (1991) 1.24
Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother (2004) 1.13
Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro. Antimicrob Agents Chemother (1990) 1.08
Antiviral activities of isometric dideoxynucleosides of D- and L-related stereochemistry. Antimicrob Agents Chemother (1995) 1.05
Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother (2011) 1.04
Inhibition of immune functions by antiviral drugs. J Clin Invest (1991) 1.04
Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proc Natl Acad Sci U S A (1996) 1.03
Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques. Antimicrob Agents Chemother (1994) 1.00
Antiviral therapy: current concepts and practices. Clin Microbiol Rev (1992) 0.96
Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. Br J Clin Pharmacol (1994) 0.96
Metabolism of 2',3'-dideoxyinosine (ddI) in human blood. Br J Clin Pharmacol (1992) 0.95
HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors. J Virol (2012) 0.92
Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. Antimicrob Agents Chemother (1995) 0.90
Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus. Antimicrob Agents Chemother (1992) 0.89
Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. Proc Natl Acad Sci U S A (1992) 0.88
Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells. Antimicrob Agents Chemother (1994) 0.86
Emergence of aminoglycoside resistance genes aadA and aadE in the genus Campylobacter. Antimicrob Agents Chemother (1990) 0.85
Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates. Antimicrob Agents Chemother (1994) 0.84
Inhibition of infectivity of human immunodeficiency virus by a novel nucleoside, oxetanocin, and related compounds. Antimicrob Agents Chemother (1989) 0.83
Effect of zidovudine on transplacental pharmacokinetics of ddI in the pigtailed macaque (Macaca nemestrina). Antimicrob Agents Chemother (1995) 0.78
Anabolic pathway of 6-methoxypurine arabinoside in cells infected with varicella-zoster virus. Antimicrob Agents Chemother (1991) 0.77
Pharmacokinetics of 2',3'-dideoxyinosine (BMY-40900), a new anti-human immunodeficiency virus agent, after administration of single intravenous doses to beagle dogs. Antimicrob Agents Chemother (1991) 0.75
Pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in the neonatal macaque (Macaca nemestrina). Antimicrob Agents Chemother (1995) 0.75
SAMHD1 enhances nucleoside-analogue efficacy against HIV-1 in myeloid cells. Sci Rep (2017) 0.75
The sequence of the human genome. Science (2001) 101.55
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13
Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses (1987) 7.85
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17
Molecular targets for AIDS therapy. Science (1990) 4.28
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Designing CD4 immunoadhesins for AIDS therapy. Nature (1989) 4.00
Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med (1975) 3.81
A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med (1984) 3.41
Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother (1998) 3.01
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (1988) 3.01
Strategies for antiviral therapy in AIDS. Nature (1987) 2.95
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther (1987) 2.92
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry (1995) 2.90
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science (1984) 2.70
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A (1989) 2.62
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest (1993) 2.27
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med (1989) 2.17
Fraud in breast-cancer trials. N Engl J Med (1994) 2.16
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med (1988) 2.08
Modified C-V flap for nipple reconstruction: our results in 50 patients. J Plast Reconstr Aesthet Surg (2008) 2.07
MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med (1999) 2.07
Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem (1994) 2.03
Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res (2001) 2.02
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet (1990) 2.02
Suppressor cells in the regulation of the immune response. Prog Clin Immunol (1977) 1.99
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A (1987) 1.96
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A (1993) 1.92
Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst (1991) 1.91
Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med (1987) 1.88
Establishment and maintenance of sister chromatid cohesion in fission yeast by a unique mechanism. EMBO J (2001) 1.87
Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther (1990) 1.87
Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. Adv Immunol (1982) 1.85
Age-related changes in the subsets and functions of human T lymphocytes. J Immunol (1978) 1.82
Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition. J Biol Chem (1988) 1.82
Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J Virol (1999) 1.81
Fc-receptors on human T lymphocytes. I. Transition of Tgamma to Tmu cells. J Immunol (1978) 1.79
Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther (1990) 1.79
Age-related decline in the in vitro and in vivo syntheses of anti-tetanus toxoid antibody in humans. J Immunol (1980) 1.78
Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. Ann Intern Med (1978) 1.78
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis (1998) 1.75
Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). Science (1984) 1.74
Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci U S A (1989) 1.74
Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. Biochemistry (1989) 1.70
Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A (1986) 1.70
Diverse transcriptional response of CD4+ T cells to stromal cell-derived factor SDF-1: cell survival promotion and priming effects of SDF-1 on CD4+ T cells. J Immunol (2001) 1.70
Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci U S A (1991) 1.67
Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity. AIDS Res Hum Retroviruses (1989) 1.67
JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci U S A (1999) 1.65
Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector. J Clin Invest (1991) 1.64
Stability studies: five years later. Am J Hosp Pharm (1988) 1.59
Defect in IgA secretion and in IgA specific suppressor cells in patients with selective IgA deficiency. Trans Assoc Am Physicians (1976) 1.59
Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med (1983) 1.58
Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol (1987) 1.57
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol (1986) 1.56
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis (1995) 1.56